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Abstract
Purpose/Objectives—Radium-223 is a first-in-class radiopharmaceutical recently approved for 
the treatment of castration-resistant prostate cancer (CRPC) in patients with symptomatic bone 
metastases. Initial studies investigating Radium-223 primarily utilized non-steroidal first-
generation anti-androgens. Since that time, newer anti-androgen therapies have demonstrated 
improved survival in patients with CRPC. It has been suggested that the rational combination of 
these newly approved agents with Radium-223 may lead to improved response rates and clinical 
outcomes. Currently, there is lack of information regarding the safety of concurrent administration 
these agents with radiopharmaceuticals. Here, we report on hematologic toxicity findings from our 
institution in patients receiving concurrent Radium-223 and next generation anti-androgen 
therapies with either enzalutamide or abiraterone.
Materials/Methods—In a retrospective study, we analyzed patients who received Radium-223 
as part of an early-access trial, and following FDA approval in May 2013, patients receiving 
Radium-223 as part of standard care. Radium-223 was given at standard dosing of 50 kBq/kg each 
month for 6 total cycles. Complete blood counts were performed prior to treatment monthly and 
following each injection. Blood counts from patients receiving Radium alone and concurrently 
with next-generation anti-androgens were compared. To date, 25 total patients were analyzed, with 
a median of five monthly doses received per patient. Fourteen patients received concurrent therapy 
during monthly Radium-223 with either enzalutamide (n=8) or abiraterone (n=6).
Results—Six patients expired due to disease progression. Two patients discontinued treatment 
due to grade 3 myelosuppression. For patients receiving either Radium alone and with concurrent 
next generation anti-androgen therapy, there did not appear to be any statistically significant 
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differences between initial and nadir blood counts. Mean change from initial neutrophil count to 
nadir was 1.9 × 106/L in patients receiving Radium alone, vs. 2.3 × 106/L in patients receiving 
concurrent therapy (p= 0.77). Mean change from initial hemoglobin value to nadir was 1.5 g/L in 
patients receiving Radium alone, vs. 1.8 g/L in patients receiving concurrent therapy (p= 0.31). 
Mean change from initial platelet count to nadir was 52.3 ×109 cells/L in patients receiving 
Radium alone vs. 70.6 ×109 cells/L in patients receiving concurrent therapy (p= 0.39). Individual 
blood counts for each measured laboratory are included in the supplemental data. PSA was stable 
or decreased in 22% of patients receiving Radium alone vs. 35% of patients receiving combination 
treatment (p=0.24).
Conclusions—Concurrent administration of Radium-223 and next generation anti-androgen 
therapies appears to be well tolerated with similar toxicities to standard administration of 
Radium-223 alone. This particular cohort of patients represents a high-risk, heavily pretreated 
group of patients with advanced metastatic disease and significant marrow burden. Despite these 
risk factors, hematologic toxicity was modest and was in the range expected for this risk group 
based on previous trials. To date, this is the first study investigating the toxicity of combination 
treatment. Further studies investigating the safety and efficacy of combination treatments are 
warranted.
Introduction
Prostate cancer is the most common solid tumor in men with over 230,000 cases diagnosed 
per year in the United States1. Approximately 30,000 men will succumb to their disease 
annually due to metastatic spread of their cancer. The current standard of care following 
diagnosis of metastatic disease includes surgical or medical castration with luteinizing 
hormone releasing hormone (LHRH) analogs or antagonists, often with first generation anti-
androgens such as bicalutamide. However, conversion to castrate resistance remains 
common2. Consensus guidelines regarding treatment after castrate resistance varies 
widely3,4. Over the last decade, the treatment landscape for patients with metastatic castrate 
resistant disease has drastically changed, with several novel agents demonstrating improved 
overall survival in several large, multi-institutional randomized trials. These new agents 
include the incorporation of cytotoxics5–7, next generation anti-androgens8–11, 
immunotherapeutics12, and radiopharmaceuticals13.
Among these newly approved agents include Radium-223, a first-in-class 
radiopharmaceutical approved for the treatment of castration-resistant prostate cancer 
(CRPC) in patients with symptomatic bone metastases14. Initial studies investigating 
Radium-223 primarily utilized non-steroidal first-generation anti-androgens or standard 
androgen suppression therapies 13,15,16. In the landmark ALSYMPCA trial, the usage of 
Radium-223 in this population demonstrated significantly improved overall survival when 
compared with placebo (median 14.9 months versus 11.3 months) and reduced the risk of 
death by 30% (hazard ratio [HR] 0.70; 95% CI 0.58–0.83; P<0.001)13. Patients previously 
receiving docetaxel were eligible for this trial, although approximately half of patients were 
not healthy enough or declined to receive it, or it was not available. Concurrent use of next 
generation anti-androgen use with either abiraterone or enzalutamide was not included.
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Currently, there is limited data regarding the sequencing of newly approved therapeutic 
agents for use in patients with metastatic CRPC due to their novel availability17,18. 
Furthermore, it has been suggested that the rational use of combination treatment may lead 
to improved response rates and clinical outcomes with minimal increase in toxicity. Unlike 
traditional cytotoxic systemic treatments, several of these new agents demonstrate non-
overlapping mechanisms of action with distinct toxicity profiles. Radium-223 in particular 
has been demonstrated to have a favorable side effect profile. In previous dose-escalation 
studies, there were no grade 3 adverse events in even the highest dose group16. In the phase 
III ALSYMPCA trial, patients receiving Radium-223 had only modest side effects, principal 
of which included myelosuppression, which was expected in a patient population with 
significant marrow infiltration. In addition, the slightly increased risk of myelosuppression 
in these patients seemed to be correlated with prior chemotherapy use19.
Next-generation anti-androgens such as abiraterone and enzalutamide appear to be attractive 
candidates for combination therapy with Radium-223. In previous studies utilizing 
abiraterone and enzalutamide in the pre-chemotherapy setting, no significant hematological 
toxicity was reported 8,11. As there appear to be non-overlapping toxicities, a novel 
treatment strategy with concurrent combination therapy may be a reasonable option. In 
addition, due to the relatively modest impact of Radium-223 on PSA control, it may be even 
preferable to include a second agent to address non-osseous disease. Given this, a number of 
patients at our institution have begun to receive combination treatment as per the discretion 
of their treating medical oncologist. Here, we report on treatment toxicity findings from our 
institution in patients receiving concurrent Radium-223 and next generation anti-androgen 
therapies with either enzalutamide or abiraterone.
Methods
This is a retrospective chart review that was conducted under an Institutional Review Board-
approved outcomes protocol. From December 2012 to September 2014, 25 consecutive 
patients with metastatic castrate resistant prostate cancer received Radium-223 treatment at a 
single institution. Patients initially received Radium-223 treatment as part of an early access 
trial (NCT01516762), then following FDA approval in May 2013, all patients received 
Radium-223 treatment as part of standard of care. Indications for Radium-223 treatment 
included patients with castration-resistant prostate cancer, ≥ 2 symptomatic bone metastases, 
and no known visceral metastatic disease. Fourteen patients who received Radium-223 also 
received concurrent enzalutamide or abiraterone during prescribed monthly injections as 
indicated by their treating medical oncologist. Patient demographics are listed on Table 1. 
Complete blood counts from patients receiving Radium alone and concurrently with next-
generation anti-androgens were compared.
Radium-223
Prior to the first administration, absolute neutrophil count (ANC) was required to be ≥ 1.5 × 
109/L, platelet count was required to be ≥ 10.0 × 109/L, and hemoglobin ≥ 10 g/dL. Five 
patients received a blood transfusion prior to treatment. Following initial treatment, 
subsequent treatment required ANC to be ≥ 1.0 × 109/L and platelet count to be ≥ 50 × 
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109/L. Radium-223 was given at standard dosing of 50 kBq/kg every 4 weeks for 6 total 
cycles. Patients were followed with monthly CBCs and routine follow up visits to assess for 
toxicity.
Systemic treatment
Patients were heavily pretreated prior to beginning radium treatment. The average number of 
systemic treatments prior to initiating Radium-223 was 3.5. Sixty-four percent of patients 
received prior Docetaxel, with median of 6 cycles (range 1–16). Eight patients were enrolled 
in experimental trials including use of an aurora kinase inhibitor, anti-prolactin receptor 
antibody, androgen biosynthesis inhibitor (orteronel), or mTOR inhibitor. Abiraterone was 
given 1,000 mg (four 250 mg tablets) administered orally once daily in combination with 
prednisone 5 mg administered orally twice daily. Enzalutamide was given 160 mg (four 40 
mg capsules) administered orally once daily. Dose was adjusted based on patient tolerability.
Toxicity
The primary goal of this study was to evaluate the incidence of hematologic adverse events 
with concurrent administration of Radium-223 and either enzalutamide or abiraterone. 
Hematologic adverse events were defined by grade 2–4 anemia, neutropenia, and 
thrombocytopenia according to Common Terminology Criteria for Adverse Events 
(CTCAE) v4.020. Complete blood counts were performed prior to treatment monthly and 
following each injection. Initial baseline labs and nadir levels during and after treatment 
were also analyzed. Mean counts amongst patients receiving Radium alone and concurrently 
with next-generation anti-androgens were compared using match-paired analysis with 
student’s t-test. Fisher’s exact test was used for binomial data. (GraphPad Prism, version 
5.00, GraphPad Software, San Diego, CA).
Results
Twenty five total patients receiving Radium-223 were evaluated. Median follow up with 
laboratory complete blood count was six months. Fourteen patients received concurrent 
treatment (8 patients received concurrent abiraterone and 6 patients received concurrent 
enzalutamide) and 11 patients received Radium alone. Median pretreatment absolute 
neutrophil count, hemoglobin, and platelets for patients receiving radium alone were 4.55 
×109 cells/L (range: 2.1–9.5), 10.95 gm/dL (range: 9.5–14.6), and 215,500/ul (range: 138–
325), respectively. Median pretreatment absolute neutrophil count, hemoglobin, and platelets 
for patients receiving concurrent treatment were 3.56 ×109 cells/L (range: 2.4–9.5), 11.2 
gm/dL (range: 9.9–13.9), and 251,000/ul (range: 134–467), respectively.
Six patients expired due to disease progression. One patient receiving Radium-223 alone 
discontinued Radium-223 due to Grade 3 anemia and one patient receiving concurrent 
abiraterone discontinued Radium-223 due to Grade 3 thrombocytopenia. Enzalutamide was 
dose-reduced in two patients due to fatigue and in one patient due to nausea and vomiting. 
Abiraterone was discontinued in one patient receiving concurrent treatment due to fatigue.
For patients receiving either Radium alone and with concurrent next generation anti-
androgen therapy, there did not appear to be any statistically significant differences between 
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initial and nadir blood counts. Figure 1 demonstrates mean absolute neutrophil counts over 
time following administration of Radium-223. Mean change from initial neutrophil count to 
nadir was 1.9 × 106/L in patients receiving Radium alone, vs. 2.3 × 106/L in patients 
receiving concurrent therapy (p= 0.77). Figure 2 demonstrates mean hemoglobin values over 
time following administration of Radium-223. Mean change from initial hemoglobin value 
to nadir was 1.5 g/L in patients receiving Radium alone, vs. 1.8 g/L in patients receiving 
concurrent therapy (p= 0.31). Figure 3 demonstrates mean platelet counts over time 
following administration of Radium-223. Mean change from initial platelet count to nadir 
was 52.3 ×109 cells/L in patients receiving Radium alone vs. 70.6 ×109 cells/L in patients 
receiving concurrent therapy (p= 0.39). There did appear to be a trend in thrombocytopenia 
in the concurrent group that did not reach statistical significance. Three of four patients 
experiencing grade 3 thrombocytopenia had previous history of docetaxel use and had 
associated advanced disease. PSA was stable or decreased in 22% of patients receiving 
Radium alone vs. 35% of patients receiving combination treatment (p=0.24). Individual 
blood counts for each measured laboratory are included in the Supplemental Digital Content. 
Supplemental Figure 1 demonstrates individual absolute neutrophil count over time. 
Supplemental Figure 2 demonstrates individual hemoglobin values over time. Supplemental 
Figure 3 demonstrates individual platelet values over time.
Hematologic adverse events are reported in Table 2. A number of patients began treatment 
with pre-existing toxicity, with almost all patients having at least Grade 1 anemia. Incidence 
of adverse events appears to be similar in both groups with no Grade 4 toxicities in either 
group.
Hematologic adverse events based on prior history of chemotherapy are reported in Table 3. 
Over one-third of patients with a prior history of docetaxel use experienced a Grade 3 
hematologic toxicity while there was only one patient who experienced a Grade 3 
hematologic toxicity who had no history of Docetaxel exposure.
Discussion
In this single-institution retrospective study, concurrent administration of Radium-223 and 
next generation anti-androgen therapies appears to be well tolerated with similar toxicities to 
standard administration of Radium-223 alone. This particular cohort of patients represents a 
high-risk, heavily pretreated group of patients with advanced metastatic disease and 
significant marrow burden. Despite these risk factors, hematologic toxicity was modest and 
was in the range expected for this risk group based on previous trials 13.
As treatment options in the metastatic prostate landscape continue to expand, there is a 
growing interest in using rational combinations of agents to improve the therapeutic ratio. 
Due to unique mechanisms of action for many of these agents, the addition of combination 
therapy may improve outcomes without a corresponding increase in toxicity. The use of 
cytotoxic therapy and radioisotope treatment has previously been explored with early 
generation radiopharmaceuticals.
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In a randomized phase II study, bone-targeted therapy for advanced prostate cancer using 
Sr-89 plus doxorubicin weekly was associated with improved survival vs doxorubicin 
alone 21. Authors from this study suggested that the combination of systemic therapy with 
bone targeted treatment improved outcomes due to dual-targeting of both epithelial and the 
stromal components of the disease. By targeting the primary tumor as well as the metastatic 
niche, a synergistic treatment response was obtained. Similarly, newer trials have reported 
promising data with regard the usage of Radium-223 with concurrent taxane-based 
chemotherapy, although data has not yet matured22.
Next-generation anti-androgen therapies with abiraterone and enzalutamide represent unique 
opportunity for combination therapy as the side effect profile from these therapies tends to 
be mild for most patients. Currently there are a number of clinical trials underway 
investigating the use of concurrent anti-androgen and radiopharmaceutical treatment. In one 
of the largest of these trials, patients will be randomized between Radium-223 alone, 
Radium-223 with abiraterone, or Radium-223 with enzalutamide (NCT02034552). Accrual 
is currently ongoing with an estimated study completion date in June 2018. While final 
results of this and other similar trials complete accrual, there is currently limited published 
data regarding the safety and efficacy of this treatment combination.
There are a number of limitations of this study. This study represents a relatively small, 
single institution retrospective experience. Patients were not prospectively stratified by pre-
treatment characteristics according to treatment group. Furthermore, a majority of patients in 
this study were heavily pretreated and may have demonstrated higher toxicity rates as a 
consequence of advanced marrow infiltration or residual chemotherapy toxicity rather than 
treatment effect. In addition, usage of concurrent treatment was not uniform amongst 
patients and was at the discretion of the treating medical oncologists. Finally, as Radium-223 
was only recently approved, the long term data regarding treatment related toxicity is still 
being evaluated.
To the authors knowledge, this report represents one of the first single institution experiences 
with concurrent treatment with Radium-223 and next generation anti-androgen therapy. 
Findings from this study suggest combination treatment is well tolerated with minimal 
toxicity. Data from this study is hypothesis-generating and future studies investigating safety 
and efficacy with combination treatment are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Absolute Neutrophil count following administration of Radium-223.
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Figure 2. 
Hemoglobin level following administration of Radium-223.
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Figure 3. 
Platelet count following administration of Radium-223.
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